Effect of Vitamin D Receptor Polymorphisms on the Development and Progression of Malignant Melanoma
Authors:
I. Špaková 1; M. Bilecová‑ rabajdová 1; M. Zábavníková 2; P. Urban 1; M. Mareková 1
Authors‘ workplace:
Ústav lekárskej a klinickej biochémie LF UPJŠ a LABMED, a. s., Košice
1; Klinika plastickej, rekonštrukčnej a estetickej chirurgie LF UPJŠ a UN LP Košice
2
Published in:
Klin Onkol 2014; 27(3): 173-177
Category:
Review
Overview
Background:
Malignant melanoma is one of the most aggressive cutaneous tumors in men and women. The risk of developing a malignant melanoma depends on several external factors along with deregulation of mutual interaction of genotype and phenotype. Nowadays, growing attention is focused on the study of the interactions of the active form of vitamin D3 with its receptor and inhibitory effect of vitamin D3 receptor polymorphisms on multiple signaling pathways involved in proliferative and metastatic processes.
Objectives:
This review article addresses the relationship between factors involved in the development of malignant melanoma through Hedgehog signaling pathway (HH). It summarizes current knowledge of malignant melanoma in regard to the role of the active form of vitamin D3 binding to vitamin D3 receptor (VDR), as well as it describes the influence of polymorphisms of VDR on the inhibition of HH. Understanding of these mechanisms and critical assessment of available data is beneficial to both primary and secondary prevention of malignant melanoma particularly by means of chemo‑ preventive substances.
Key words:
vitamin D3 – Hedgehog signalisation – melanoma – calcitriol – skin cancer
This work was supported by by the grant DIAGONKO ITMS:
26220220153.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Submitted:
21. 12. 2013
Accepted:
25. 2. 2014
Sources
1. Grimaldi AM, Cassidy PB, Leachmann S et al. Novel approaches in melanoma prevention and therapy. Cancer Treat Res 2014; 159: 443– 455. doi: 10.1007/ 978- 3- 642- 38007- 5_25.
2. Kappelmann M, Bosserhoff A, Kuphal S. AP‑ 1/ c‑ Jun transcription factors: regulation and function in malignant melanoma. Eur J Cell Biol 2014; 93(1– 2): 76– 81. doi: 10.1016/ j.ejcb.2013.10.003.
3. Bosserhoff A (ed.). Melanoma development molecular biology, genetics and clinical application. Springer 2011: 376.
4. Havránková M. Záchyt dermatologických malignít v ambulancií praktického lekára. Via pract 2007; 4(5): 244– 246.
5. Krajsová I. Melanom. In: Krajsová I (ed.). Melanom. Maxdorf 2006.
6. Polsky D, Cordon‑ Cardo C, Houghton A. 19. Molecular biology of melanoma in the molecular basis of cancer. 2nd ed. Mendensol J et al. Elsevier Inc 2001.
7. Szyszka P, Zmijewski MA, Slominski AT. New vitamin D analogs as potential therapeutics in melanoma. Expert Review of Anticancer Theraphy 2012; 12(12): 585– 599. doi: 10.1586/ era.12.40.
8. Gandini S, Raimondi S, Gnagnarella P et al. Vitamin D and skin cancer: a meta‑analysis. Eur J Cancer 2009; 45(4): 634– 641. doi: 10.1016/ j.ejca.2008.10.003.
9. Madhunapantula SV, Robertson GP. Is B‑ Raf a good therapeutic target for melanoma and other malignancies? Cancer Res 2008; 68(1): 5– 8. doi: 10. 1158/ 0008- 5472.CAN‑ 07-2038.
10. Gollob JA, Wilhelm S, Carter C et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/ MEK/ ERK signal transduction pathway. Semin Oncol 2006; 33(4): 392– 406.
11. Russo AE, Torrisi E, Bevelacqua Y et al. Melanoma: molecular pathogenesis and emerging target therapies (review). Int J Oncol 2009; 34(6): 1481– 1489.
12. Baker AR, McDonnell DP, Hughes M et al. Cloning the expression of full‑ length cDNA encoding human vitamin D receptor. Proc Nat Acad Sci USA 1988; 85(10): 3294– 3298.
13. Halsall JA, Osborne JE, Potter L et al. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma. Br J Cancer 2004; 91(4): 765– 770.
14. Essa S, Denzer N, Mahlknecht U et al. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J Steroid Biochem Mol Biol 2010; 121(1– 2): 110– 113. doi: 10.1016/ j.jsbmb.2010.02.003.
15. Palmer HG, Anjos‑ Afonso F, Carmeliet G et al. The vitamin D receptor is a wnt effector that controls hair follicle differentiation and specifies tumor type in adult epidermis. PLoS One 2008; 3(1): 1483. doi: 10.1371/ journal.pone.0001483.
16. Ishibashi M, Arai M, Tanaka S et al. Antiproliferative and apoptosis‑ inducing effects of lipophilic vitamins on human melanoma A375 cells in vitro. Biol Pharm Bull 2012; 35(1): 10– 17.
17. Essa S, Reichrath S, Mahlknecht U et al. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines. Anticancer Res 2012; 32(1): 383– 389.
18. Haussler MR, Whitfield GK, Haussle CA et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13(3): 325– 349.
19. Darwish H, DeLuca HF. Vitamin D‑ regulated gene expression. Crit Rev Eukaryot Gene Expr 1993; 3(2): 89– 116.
20. Freedman LP. Increasing the complexity of coactivation in nuclear receptor signalin. Cell 1999; 97(1): 5– 8.
21. Nolan‑ Stevaux O, Lau J, Morgan L et al. GLI1 is regulated through Smoothened independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009; 23(1): 24– 36. doi: 10.1101/ gad.1753809.
22. Wang Y, McMahon AP, Allen BL. Shifting paradigms in Hedgehog signaling. Curr Opin Cell Biol 2007; 19(2): 159– 165.
23. So PL, Fujimoto MA, Epstein EH Jr. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol Cancer Ther 2008; 7(5): 1275– 1284. doi: 10.1158/ 1535- 7163.MCT‑ 07- 2043.
24. Bijlsma MF, Spek CA, Zivkovic D et al. Repression of smoothened by patched‑ dependent (pro‑)vitamin D3 secretion. Plos Biol 2006; 4(8): e232.
25. Bikle DD. Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism. J Invest Dermatol 2008; 128(10): 2357– 2361. doi: 10.1038/ jid.2008.249.
26. Holick MF. Calcium plus vitamin D and the risk of colorectal cancer. N Engl J Med 2006; 354(21): 2287– 2288.
27. Tang JY, Xiao TZ, Oda Y et al. Vitamin D3 inhibits hedgehog signaling and proliferation in basal cell carcinomas. Cancer Prev Res (Phila) 2011; 4(5): 744– 751. doi: 10.1158/ 1940- 6207.CAPR‑ 10- 0285.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2014 Issue 3
Most read in this issue
- Very Late Effects of Radiotherapy – Limiting Factor of Current Radiotherapy Techniques
- Inverted Papiloma and Its Rare Forms
- Case Report of a Patient with Advanced and Disseminated Gastric Carcinoma Treated by S-1
- Analysis of Disease‑free Survival and Overall Survival in Patients with Luminal A Breast Cancer Stratified According to TNM